Veterinary Medicines Directorate

Veterinary Medicines Directorate Woodham Lane, New Haw, Addlestone, Surrey, KT15 3LS Telephone +44 (0)1932 336911

## **Post Authorisation Assessments**

For details of post authorisation assessments prior to 1<sup>st</sup> January 2021, please refer to the <u>EMA</u> website.

## MiPet Easecto 5 mg Chewable Tablets for Dogs 1.3–2.5 kg

Vm 42058/5038

-	00 February 0004	Change in the shalf life on stangers can differe of the finishest
•	23 February 2024	Change in the shelf-life or storage conditions of the finished product.
•	22 December 2023	Editorial changes to Part 2 of the dossier.
		Editorial changes to Part 2 of the dossier.
		Editorial changes to Part 2 of the dossier.
		Editorial changes to Part 2 of the dossier.
		Minor changes to an approved test procedure for the finished
		product.
		Minor changes to an approved test procedure for the finished
		product.
		Minor changes to an approved test procedure for the finished
		product.
•	18 October 2023	Extension of the re-test period of the active substance where
		no Ph. Eur. Certificate of Suitability covering the retest period
		is part of the approved dossier.
•	18 September 2023	Minor changes in the manufacturing process of the drug
	-	product intermediate.
		Addition of a site for the manufacturing process of the drug
		product intermediate.
•	14 September 2023	Change in batch size of the drug product intermediate.
		Minor changes to the registered method for the drug product
		intermediate.
		Minor changes to the registered method for the drug product
		intermediate.
		Minor changes to the registered method for the drug product
		intermediate.
•	14 September 2023	Update of SPC/QRD in line with new version.
•	03 August 2023	Change in batch size of finished product.
		Change in batch size of finished product.
_		Change in batch size of finished product.
•	17 April 2023	Addition of an alternative supplier of a starting material.
•	17 February 2023	Additional indication: For reduction of the risk of infection with
		Babesia canis canis via transmission by Dermacentor
		reticulatus for 28 days after treatment. The effect is indirect
		due to the product's activity against the vector.
•	17 January 2023	Associated warning in Section 4.4 Unlimited renewal
•	06 January 2023	Addition of a primary packaging site.
•	04 January 2023	Addition of a secondary packaging site.
•	04 November 2022	Correction in the name/address of a manufacturer of an active
		substance.
•	20 October 2022	Changes to labelling to include GB details in blue box.
•	07 October 2022	Deletion of suppliers for packaging components.
•	23 August 2022	Change in name of a supplier of the active substance.
		•
	Ũ	Change in name of a supplier of the active substance.

	Deletion of a supplier of the active substance. Deletion of a supplier of the active substance.
• 30 May 2022	Change in the name of a supplier of starting material.
• 09 March 2022	Changes to a test procedure for the immediate packaging of the active substance. Change in manufacturer of the active substance.